GTC Biotherapeutics (fka GTCB)

[croumagnon]

"Unsophisticated biotech investors always fall for these Fast Track PR’s, which mean almost nothing."

I think you are overdoing it with the lack of importance of fast-track status. You have even defeated your own argument regarding that by saying that Priority review would be a big deal but not fast track. If you carry tghat argument a bit deeper you will see that Priority review is almost implicit when a product gets fast-track. It is not always the case, but more often than not because:

http://www.accessdata.fda.gov/scripts/cder/onctools/Accel.cfm#FastTrack

"The Fast Track designation is intended for the combination of a product and a claim that addresses an unmet medical need"
and:
"A Priority designation is intended for those products that address unmet medical needs"

So you see, once the FDA has recognized ATryn as adressing "unmet medical needs", it makes it so much easier to get Priority Review which, as you say, shaves 4 months from the regulatory process and is a big deal.

Additionally, receiving fast-track desuignation gets the company to have a lot more collaboration and meetings with the FDA about ATryn, which is clearly a good thing as the FDA becomes GTCB's soul partner in the BLA submission...

"LOL—why don’t you tell us who “they” are? I can’t stand the suspense."

I think the "They" ("the ones that probably will bring it down") as implied by the previous poster, are probably in this case a few people trading in a basement somewhere and having about $500,000 capital to trade with on a daily basis. With that, they are able usually to control the price action of GTCB and pin the price as we have seen over a long time. However, when we get a decent volume, as is the case today, these fake mini-hedgie traders in the basement are unable to do much. Hopefully this high volume will continue... (are you one of those traders Dew, and are you using the opportunity to takeover the company on the cheap?? LOL)